ArticleInsights into imaging2026
Myocardial work in light-chain and transthyretin-related amyloidosis with preserved ejection fraction: a cardiovascular magnetic resonance study.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesTo investigate pressure-volume loop (PV-loop) changes by cardiovascular magnetic resonance (CMR) imaging in cardiac amyloidosis (CA) patients with preserved left ventricular ejection fraction (LVEF), and to assess PV-loop parameters' potential as subtype differential diagnostic markers. MATERIALS AND
methodsBetween May 2017 and September 2023, 100 consecutive confirmed CA patients (14 transthyretin-related [ATTR-CA] and 86 light-chain [AL-CA]) and 40 age- and sex-matched healthy controls (HCs) were prospectively enrolled. PV-loop parameters were derived from CMR cine images and brachial blood pressure. Clinical and CMR parameters were compared between CA patients and HCs, as well as between CA subtypes. The correlations between PV-loop parameters and clinical and imaging parameters were assessed. Furthermore, the differential diagnostic performance of these PV-loop parameters was evaluated using the area under the receiver operating characteristic curve (ROC-AUC). Bootstrapping was performed 2000 times for internal validation.
resultsCompared to HCs, CA patients showed significantly lower stroke work index, potential energy index (PEI), and work efficiency (all p < 0.001). AL-CA patients had higher N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (2358.00 [IQR: 903.25, 5559.00] vs 810.00 [IQR: 269.00, 1136.01] pg/mL, p = 0.002) and lower PEI (0.13 [IQR: 0.07, 0.15] vs 0.15 [IQR: 0.13, 0.19] J/m², p = 0.025) than ATTR-CA patients. NT-proBNP (β = -1.94, OR = 0.14, 95% CI: 0.03-0.64, p = 0.016) and PEI (β = 0.20, OR = 1.23, 95% CI: 1.07-1.44, p = 0.007) were independent predictors for AL-CA vs ATTR-CA differentiation, and combining these two parameters enhanced the diagnostic performance (bootstrapping AUC 0.847).
conclusionBy providing pathophysiological insights into the distinctions between AL-CA and ATTR-CA, PV-loop parameters have the potential to serve as a complementary, contrast-free approach for differential diagnosis. KEY POINTS: Question PV-loop changes by CMR in CA patients with preserved LVEF remain unknown. Findings Light-chain CA patients with preserved LVEF had higher NT-proBNP levels and lower PEI than transthyretin-related CA patients. Critical relevance statement The CMR-derived PV-loop parameters revealed pathophysiological differences between the two subtypes of CA, suggesting potential differential diagnostic value.
Indexed as
Identifiers
42855647What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.